Nanoscience Approaches in Treating Urinary Tract Infection with Existing Antibiotic Therapy

Abstract

A serious worldwide health emergency has been brought on by the growth of multidrug-resistant (MDR) microorganisms, which are difficult to treat with traditional antimicrobial drugs. This emphasises how urgently novel therapeutic approaches are needed to combat antimicrobial drug resistance (ABR). To increase the efficacy of treatment for resistant microorganisms, one such tactic, known as nAbts mixes antimicrobial medications with nanoparticles. This work looks at the development of nano-based treatment systems to treat ABR, specifically urinary tract infections brought on by pathogenic microbes. Important results show that nAbts are more effective than conventional antibiotics. For instance, in vitro research showed that silver nanoparticle-based nAbts decreased bacterial growth in ciprofloxacin-resistant Escherichia coli strains by 98%, as opposed to the 30–40% reduction seen with ciprofloxacin alone. The capacity of the nanoparticles to break down bacterial cell walls, boost medication penetration, and enable targeted delivery—thereby circumventing resistance mechanisms—is responsible for this notable increase in antimicrobial activity. With their capacity to break down bacterial cell walls and promote intracellular drug accumulation, nAbts hold enormous promise for defeating resistance and providing a major breakthrough in the management of multidrug-resistant illnesses. The promise of nAbts to offer safer, more focused, and more successful treatment alternatives for ABR is highlighted in this publication.